Beyond the brain: curcumin as a multi-target neuropharmacological modulator of the gut–brain axis in major depressive disorder and Parkinson’s disease
Naunyn-Schmiedeberg's Archives of Pharmacology · 07.11.2026
DOI: 10.1007/s00210-026-06013-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 07.11.2026. Verfasst von Uzma Noor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, College of Basic Medical Sciences, Liaoning Provincial Key Laboratory of Cerebral Diseases, National-Local Joint Engineerin…. Die Arbeit nennt 260 Literaturangaben.
Abstract (Originalsprache)
Curcumin, the principal polyphenol of Curcuma longa, has been proposed as a multi-target neuropharmacological agent for neuropsychiatric and neurodegenerative disorders. We propose that major depressive disorder (MDD) and Parkinson's disease (PD) share a convergent gut-brain axis dysfunction, and that curcumin can serve as a pharmacological probe to test whether this convergent pathway is causally relevant. This narrative review evaluates that hypothesis. We conducted a structured literature search across PubMed, Scopus, Web of Science, Google Scholar, and CNKI using predefined search terms. This is a narrative review with a structured search strategy rather than a systematic review; no formal risk-of-bias assessment or meta-analysis was performed. From 2256 identified records, 112 primary studies were selected for synthesis after dual screening and consensus resolution. Findings should be interpreted as hypothesis-generating rather than as a quantitative synthesis. We propose a differential metabolite-sensitivity threshold model as a testable hypothesis: shared dysbiosis-related metabolic and inflammatory disturbances may affect serotonergic function earlier than dopaminergic function because depressed mood manifests at modest neurotransmitter deficits, whereas nigrostriatal dopaminergic neurons possess substantial compensatory reserve. Preclinical studies indicate that curcumin exerts prebiotic-like effects, promotes short-chain fatty acid-producing bacteria, suppresses NF-κB-dependent neuroinflammation, restores BDNF signaling, inhibits α-synuclein aggregation, and improves depressive- and PD-like behaviors. These actions map onto convergent gut-brain pathways involving short-chain fatty acid deficiency, tryptophan-kynurenine imbalance, monoaminergic precursor depletion, and neuroinflammation. This model generates four testable predictions: (P1: functional dysbiosis convergence; P2: temporal precedence of depressed mood; P3: curcumin's multi-node modulation; and P4: clinical benefit with adequate bioavailability). Preclinical evidence supports functional convergence (P1), temporal asymmetry (P2), and curcumin's multi-target actions (P3), but clinical benefit in MDD-PD comorbidity (P4) remains untested. However, curcumin's clinical translation remains limited by poor oral bioavailability (~ 1% for standard extracts) and the absence of randomized trials in MDD-PD comorbidity. We conclude that the convergent gut-brain hypothesis is plausible, partially supported, and directly testable, and we specify the minimal studies required to confirm or falsify it.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, College of Basic Medical Sciences, Liaoning Provincial Key Laboratory of Cerebral Diseases, National-Local Joint Engineering Research Center for Drug Research and Development (R&D) of Neurodege…
- Department of Pathogenic Biology, College of Basic Medical Sciences, Liaoning Provincial Key Laboratory of Infectious Diseases, Dalian Medical University, Dalian, Liaoning, 116044, China.
- Laboratory of Infectious Diseases, School of Chemistry and Chemical Engineering, National Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou, Gansu, 730000, China.
- Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an Jiaotong University, No. 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.
- National-Local Joint Engineering Research Center for Drug Research and Development (R&D) of Neurodegenerative Diseases, Dalian Medical University, Dalian, 116044, Liaoning, China. lishao89@dmu.edu.cn.
Zitieren
APA
Noor, U., Khan, I., Khan, I., Kong, Y., Khan, S. H., & Li, S. (2026). Beyond the brain: curcumin as a multi-target neuropharmacological modulator of the gut–brain axis in major depressive disorder and Parkinson’s disease. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-06013-1
Vancouver
Noor U, Khan I, Khan I, Kong Y, Khan SH, Li S. Beyond the brain: curcumin as a multi-target neuropharmacological modulator of the gut–brain axis in major depressive disorder and Parkinson’s disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-06013-1
BibTeX
@article{Noor2026,
author = {Noor, Uzma and Khan, Imran and Khan, Ikram and Kong, Yue and Khan, Shah Hassan and Li, Shao},
title = {Beyond the brain: curcumin as a multi-target neuropharmacological modulator of the gut–brain axis in major depressive disorder and Parkinson’s disease},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-06013-1}
}
EUVIMED